What is BigHat Biosciences?
AI-guided antibody therapeutics company
- Category
- AI drug discovery
- Headquarters
- San Mateo, CA
- Founded
- 2019
- Employees
- Series B biotech; exact headcount not disclosed
- Total funding
- At least $145M reported; company says >$100M
- Valuation
- Private; valuation not publicly disclosed
What is BigHat Biosciences?
BigHat Biosciences designs safer and more effective antibody therapies using machine learning, synthetic biology, and an integrated wet lab. The company is a Series B biotech in San Mateo with partnered and wholly owned therapeutic programs.
BigHat Biosciences designs safer and more effective antibody therapies using machine learning, synthetic biology, and an integrated wet lab. The company is a Series B biotech in San Mateo with partnered and wholly owned therapeutic programs. Pipeline of wholly owned and partnered therapeutic programs.
As of June 2026, the most conservative read is to use public operating milestones and disclosed financing rather than invent private revenue or internal budgets. For sellers, the relevant buying signal is the company's current stage: Private; valuation not publicly disclosed, Series B biotech; exact headcount not disclosed, and the functional needs created by its product and market position.
Sources:BigHat homepageBigHat careers
What does BigHat Biosciences offer?
BigHat offers the Milliner platform, antibody design campaigns, wet-lab characterization, developability optimization, therapeutic programs, and biopharma partnerships.
- Milliner platform· AI/ML
- Wet-lab characterization· Lab
- Antibody design· Therapeutics
- Developability optimization· Therapeutics
- Partnered programs· Business development
- Wholly owned pipeline· Pipeline
Sources:BigHat technologyBigHat homepage
How does BigHat Biosciences make money?
BigHat makes money through strategic biopharma collaborations, platform partnerships, and future therapeutic economics rather than published SaaS pricing. No public price list exists for discovery partnerships.
BigHat makes money through strategic biopharma collaborations, platform partnerships, and future therapeutic economics rather than published SaaS pricing. No public price list exists for discovery partnerships.
The company does not publish a complete standardized enterprise price card for every buyer segment. Growth is therefore best assessed through public usage, customer, funding, acquisition, or public-company data, and seller outreach should tie to measurable product, compliance, infrastructure, or go-to-market outcomes.
Sources:BigHat partneringBigHat careers
Who leads BigHat Biosciences?
BigHat is led by CEO and co-founder Peyton Greenside after Mark DePristo stepped down and passed the CEO role to her in 2025.
- Peyton GreensideCEO and co-founderCEO since 2025; co-founder since 2019Deep learning and computational biology leader.
- Mark DePristoCo-founder; former CEOCEO 2019-2025Former Broad Institute and Google Brain Genomics leader.
- Eddie AbramsChief Information OfficerListed on about pageLeads information systems and technology.
- Hunter ElliottVP, Machine LearningListed on about pageLeads ML function for antibody design.
How do you contact BigHat Biosciences's leadership?
BigHat publishes info@bighatbio.com and partnering@bighatbio.com; personal executive emails are not public.
Personal executive email format not verified; use public company aliases/contact pagesSources:BigHat contactBigHat careers
How much funding has BigHat Biosciences raised?
BigHat raised $19M Series A in 2021, $75M Series B in 2022 bringing company-reported funding to $100M, and CB Insights reports a $45M Series B-II in April 2025.
BigHat raised $19M Series A in 2021, $75M Series B in 2022 bringing company-reported funding to $100M, and CB Insights reports a $45M Series B-II in April 2025.
Where valuation is not currently disclosed, this profile uses the latest public financing or exit value and explicitly avoids private marks. a16z provenance is included from the official investment list where relevant, and public/acquired companies are treated through their capital-history or exit lens.
How did BigHat Biosciences get here?
BigHat advanced from an a16z-backed AI antibody platform to a Series B biotech with internal and partnered therapeutic programs.
- 2019FoundedMark DePristo and Peyton Greenside founded BigHat.
- Feb. 2021Series ARaised $19M led by Andreessen Horowitz.
- Jun. 2022Series BRaised $75M; total funding reached about $100M.
- 2025Leadership transitionPeyton Greenside became CEO.
- Apr. 2025Series B-II reportCB Insights reported a $45M Series B-II.
Who are BigHat Biosciences's competitors?
BigHat competes with AI biologics, antibody discovery, and protein-design companies.
- Generate:BiomedicinesGenerative biology platform for protein therapeutics.
- AbsciAI drug creation company focused on biologics.
- AntiverseAI antibody design platform.
- AbCelleraAntibody discovery platform with clinical and partner programs.
- Iambic TherapeuticsAI-native drug discovery company with small-molecule focus.
BigHat Biosciences — frequently asked questions
